29 April 2021

Interview with Aris Persidis, President of BioVista

As patent protections expire, drug repositioning has become a matter of intense interest. Aris Persidis founded Biovista in 2005 and has focused on using artificial intelligence to match drugs against any and all mechanisms, pathways, diseases and clinical outcomes.

Since the outbreak of the COVID-19 pandemic Biovista has put forward six possible drugs that could potentially be repositioned for treatment of COVID-19 symptoms.

We will be speaking to Persidis about the future of biotechnology and the impact of Biovista on modern medicine.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk